Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.

Chaumais, Marie-Camille; Djessas, Mohamed Reda Amar; Thuillet, Raphaël; Cumont, Amélie; Tu, Ly; Hebert, Guillaume; Gaignard, Pauline; Huertas, Alice; Savale, Laurent; Humbert, Marc; Guignabert, Christophe

Chaumais, Marie-Camille; Djessas, Mohamed Reda Amar; Thuillet, Raphaël; Cumont, Amélie; Tu, Ly; Hebert, Guillaume; Gaignard, Pauline; Huertas, Alice; Savale, Laurent; Humbert, Marc; Guignabert, Christophe.

Affiliation

Chaumais MC; INSERM, UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies¼, Hôpital Marie Lannelongue, 92350, Le Plessis-Robinson, France.
Djessas MRA; Université Paris-Saclay, Faculté de Pharmacie, 92290, Châtenay-Malabry, France.
Thuillet R; Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pharmacie, Hôpital Bicêtre, 94270, Le Kremlin-Bicêtre, France.
Cumont A; INSERM, UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies¼, Hôpital Marie Lannelongue, 92350, Le Plessis-Robinson, France.
Tu L; Université Paris-Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France.
Hebert G; INSERM, UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies¼, Hôpital Marie Lannelongue, 92350, Le Plessis-Robinson, France.
Gaignard P; Université Paris-Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France.
Huertas A; INSERM, UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies¼, Hôpital Marie Lannelongue, 92350, Le Plessis-Robinson, France.
Savale L; Université Paris-Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France.
Humbert M; INSERM, UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies¼, Hôpital Marie Lannelongue, 92350, Le Plessis-Robinson, France.
Guignabert C; Université Paris-Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France.

Cardiovasc Res ; 117(5): 1391-1401, 2021 04 23.

Article in En | MEDLINE | ID: mdl-32653925

Subject(s)

Aminobutyrates/pharmacology; Angiotensin II Type 1 Receptor Blockers/pharmacology; Biphenyl Compounds/pharmacology; Bosentan/pharmacology; Endothelin Receptor Antagonists/pharmacology; Protease Inhibitors/pharmacology; Pulmonary Arterial Hypertension/drug therapy; Pulmonary Artery/drug effects; Valsartan/pharmacology; Vascular Remodeling/drug effects; Animals; Atrial Natriuretic Factor/blood; Cell Proliferation/drug effects; Cells, Cultured; Cyclic GMP/blood; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension/drug therapy; Familial Primary Pulmonary Hypertension/metabolism; Familial Primary Pulmonary Hypertension/physiopathology; Humans; Male; Muscle, Smooth, Vascular/drug effects; Muscle, Smooth, Vascular/metabolism; Muscle, Smooth, Vascular/pathology; Myocytes, Smooth Muscle/drug effects; Myocytes, Smooth Muscle/metabolism; Myocytes, Smooth Muscle/pathology; Neprilysin/antagonists & inhibitors; Pulmonary Arterial Hypertension/metabolism; Pulmonary Arterial Hypertension/physiopathology; Pulmonary Artery/metabolism; Pulmonary Artery/physiopathology; Rats, Wistar

Key words

Cardiac dysfunction; Entresto; Pulmonary arterial hypertension; Pulmonary vascular remodelling

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Protease Inhibitors / Pulmonary Artery / Biphenyl Compounds / Angiotensin II Type 1 Receptor Blockers / Vascular Remodeling / Endothelin Receptor Antagonists / Valsartan / Bosentan / Pulmonary Arterial Hypertension / Aminobutyrates Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Cardiovasc Res Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google